Global Digital Therapeutics

Digital Therapeutics Comprehensive Study by Disease (Diabetes, Obesity, Cardiovascular Diseases (CVD), Central Nervous System (CNS) Disease, Gastrointestinal Disorders (GID), Respiratory Diseases, Smoking Cessation, Others), Sales Channel (Business-to-business (B2B), Business-to-consumers (B2C)), Component (Software, Devices) Players and Region - Global Market Outlook to 2028

Digital Therapeutics Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 21.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Digital Therapeutics Market Overview:
Digital therapeutics refers to software products which are used in treatment of medical condition. These products are similar to consumer wellness applications as it allows users to take control over their own health. This treatment method is based on behavioral therapy treatment. It can be used to cure number of diseases which include dementia, type-II diabetes, obesity, anxiety and depression. Growing prevalence of chronic diseases are expected to supplement the demand for digital therapeutics. As per latest study released by AMA Research, the Global Digital Therapeutics market is expected to see growth rate of 21.7%

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Billion)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Adoption of IoT and AI in Healthcare Industries and Growing Prevalence of mHealth

Market Growth Drivers:
Growing Focus on Reducing Cost in Healthcare and Rising Number of Chronic Diseases

Challenges:
Working in Traditional Healthcare Providers for Digital-therapeutics Companies

Restraints:
Growing Number of Cyber Threat and Data Privacy Concerns and Lack of Awareness in Emerging Countries

Opportunities:
Growing Number of Startups Fueled by Rising Investment and Rising Cognitive Behavioral Therapy Treatment

Competitive Landscape:
The key manufacturers are targeting the innovations of the services with better quality, and better technical characteristics, and also assist in providing and humanizing the after-sale service to the consumers. The key players are probable to keep a stronghold on the market over the anticipated period. The key players are accepting strategic decisions and are thinking about mergers and acquisitions in order to maintain their presence in the market.
Some of the key players profiled in the report are Proteus Digital Health. Inc (United States), Omada Health, Inc (United States), Welldoc, Inc (United States), Livongo Health (United States) and Mango Health Inc (United States). Additionally, following companies can also be profiled that are part of our coverage like 2 Morrow (United States), Propeller Health (United States), Twine Health (Fitbit) (United States) and Canary Health (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Digital Therapeutics market by 2028. Considering Market by Disease, the sub-segment i.e. Diabetes will boost the Digital Therapeutics market. Considering Market by Sales Channel, the sub-segment i.e. Business-to-business (B2B) will boost the Digital Therapeutics market. Considering Market by Component, the sub-segment i.e. Software will boost the Digital Therapeutics market.

Latest Market Insights:
In November 2023, Propeller Health has launched its new platform, Propeller Connect, which provides real-time inhaler use data and personalized feedback to help people with asthma manage their condition.

In November 2023, Pear Therapeutics, a leading developer of prescription digital therapeutics (PDTs), has partnered with Boehringer Ingelheim, a global pharmaceutical company, to develop and commercialize PDTs for respiratory diseases.

What Can be Explored with the Digital Therapeutics Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Digital Therapeutics Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Digital Therapeutics
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Digital Therapeutics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Digital Therapeutics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Digital Therapeutics Service Providers, System Integrators, Potential Investors, Research Institutes, Market and Research Firms and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Disease
  • Diabetes
  • Obesity
  • Cardiovascular Diseases (CVD)
  • Central Nervous System (CNS) Disease
  • Gastrointestinal Disorders (GID)
  • Respiratory Diseases
  • Smoking Cessation
  • Others

By Sales Channel
  • Business-to-business (B2B)
  • Business-to-consumers (B2C)

By Component
  • Software
  • Devices

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Focus on Reducing Cost in Healthcare
      • 3.2.2. Rising Number of Chronic Diseases
    • 3.3. Market Challenges
      • 3.3.1. Working in Traditional Healthcare Providers for Digital-therapeutics Companies
    • 3.4. Market Trends
      • 3.4.1. Adoption of IoT and AI in Healthcare Industries
      • 3.4.2. Growing Prevalence of mHealth
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Digital Therapeutics, by Disease, Sales Channel, Component and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Digital Therapeutics (Value)
      • 5.2.1. Global Digital Therapeutics by: Disease (Value)
        • 5.2.1.1. Diabetes
        • 5.2.1.2. Obesity
        • 5.2.1.3. Cardiovascular Diseases (CVD)
        • 5.2.1.4. Central Nervous System (CNS) Disease
        • 5.2.1.5. Gastrointestinal Disorders (GID)
        • 5.2.1.6. Respiratory Diseases
        • 5.2.1.7. Smoking Cessation
        • 5.2.1.8. Others
      • 5.2.2. Global Digital Therapeutics by: Sales Channel (Value)
        • 5.2.2.1. Business-to-business (B2B)
        • 5.2.2.2. Business-to-consumers (B2C)
      • 5.2.3. Global Digital Therapeutics by: Component (Value)
        • 5.2.3.1. Software
        • 5.2.3.2. Devices
      • 5.2.4. Global Digital Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Digital Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Proteus Digital Health. Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Omada Health, Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Welldoc, Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Livongo Health (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mango Health Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
  • 7. Global Digital Therapeutics Sale, by Disease, Sales Channel, Component and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Digital Therapeutics (Value)
      • 7.2.1. Global Digital Therapeutics by: Disease (Value)
        • 7.2.1.1. Diabetes
        • 7.2.1.2. Obesity
        • 7.2.1.3. Cardiovascular Diseases (CVD)
        • 7.2.1.4. Central Nervous System (CNS) Disease
        • 7.2.1.5. Gastrointestinal Disorders (GID)
        • 7.2.1.6. Respiratory Diseases
        • 7.2.1.7. Smoking Cessation
        • 7.2.1.8. Others
      • 7.2.2. Global Digital Therapeutics by: Sales Channel (Value)
        • 7.2.2.1. Business-to-business (B2B)
        • 7.2.2.2. Business-to-consumers (B2C)
      • 7.2.3. Global Digital Therapeutics by: Component (Value)
        • 7.2.3.1. Software
        • 7.2.3.2. Devices
      • 7.2.4. Global Digital Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Digital Therapeutics: by Disease(USD Billion)
  • Table 2. Digital Therapeutics Diabetes , by Region USD Billion (2017-2022)
  • Table 3. Digital Therapeutics Obesity , by Region USD Billion (2017-2022)
  • Table 4. Digital Therapeutics Cardiovascular Diseases (CVD) , by Region USD Billion (2017-2022)
  • Table 5. Digital Therapeutics Central Nervous System (CNS) Disease , by Region USD Billion (2017-2022)
  • Table 6. Digital Therapeutics Gastrointestinal Disorders (GID) , by Region USD Billion (2017-2022)
  • Table 7. Digital Therapeutics Respiratory Diseases , by Region USD Billion (2017-2022)
  • Table 8. Digital Therapeutics Smoking Cessation , by Region USD Billion (2017-2022)
  • Table 9. Digital Therapeutics Others , by Region USD Billion (2017-2022)
  • Table 10. Digital Therapeutics: by Sales Channel(USD Billion)
  • Table 11. Digital Therapeutics Business-to-business (B2B) , by Region USD Billion (2017-2022)
  • Table 12. Digital Therapeutics Business-to-consumers (B2C) , by Region USD Billion (2017-2022)
  • Table 13. Digital Therapeutics: by Component(USD Billion)
  • Table 14. Digital Therapeutics Software , by Region USD Billion (2017-2022)
  • Table 15. Digital Therapeutics Devices , by Region USD Billion (2017-2022)
  • Table 16. South America Digital Therapeutics, by Country USD Billion (2017-2022)
  • Table 17. South America Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 18. South America Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 19. South America Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 20. Brazil Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 21. Brazil Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 22. Brazil Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 23. Argentina Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 24. Argentina Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 25. Argentina Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 26. Rest of South America Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 27. Rest of South America Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 28. Rest of South America Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 29. Asia Pacific Digital Therapeutics, by Country USD Billion (2017-2022)
  • Table 30. Asia Pacific Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 31. Asia Pacific Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 32. Asia Pacific Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 33. China Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 34. China Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 35. China Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 36. Japan Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 37. Japan Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 38. Japan Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 39. India Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 40. India Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 41. India Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 42. South Korea Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 43. South Korea Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 44. South Korea Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 45. Taiwan Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 46. Taiwan Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 47. Taiwan Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 48. Australia Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 49. Australia Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 50. Australia Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 51. Rest of Asia-Pacific Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 52. Rest of Asia-Pacific Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 53. Rest of Asia-Pacific Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 54. Europe Digital Therapeutics, by Country USD Billion (2017-2022)
  • Table 55. Europe Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 56. Europe Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 57. Europe Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 58. Germany Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 59. Germany Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 60. Germany Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 61. France Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 62. France Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 63. France Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 64. Italy Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 65. Italy Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 66. Italy Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 67. United Kingdom Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 68. United Kingdom Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 69. United Kingdom Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 70. Netherlands Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 71. Netherlands Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 72. Netherlands Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 73. Rest of Europe Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 74. Rest of Europe Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 75. Rest of Europe Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 76. MEA Digital Therapeutics, by Country USD Billion (2017-2022)
  • Table 77. MEA Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 78. MEA Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 79. MEA Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 80. Middle East Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 81. Middle East Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 82. Middle East Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 83. Africa Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 84. Africa Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 85. Africa Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 86. North America Digital Therapeutics, by Country USD Billion (2017-2022)
  • Table 87. North America Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 88. North America Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 89. North America Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 90. United States Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 91. United States Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 92. United States Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 93. Canada Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 94. Canada Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 95. Canada Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 96. Mexico Digital Therapeutics, by Disease USD Billion (2017-2022)
  • Table 97. Mexico Digital Therapeutics, by Sales Channel USD Billion (2017-2022)
  • Table 98. Mexico Digital Therapeutics, by Component USD Billion (2017-2022)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Digital Therapeutics: by Disease(USD Billion)
  • Table 105. Digital Therapeutics Diabetes , by Region USD Billion (2023-2028)
  • Table 106. Digital Therapeutics Obesity , by Region USD Billion (2023-2028)
  • Table 107. Digital Therapeutics Cardiovascular Diseases (CVD) , by Region USD Billion (2023-2028)
  • Table 108. Digital Therapeutics Central Nervous System (CNS) Disease , by Region USD Billion (2023-2028)
  • Table 109. Digital Therapeutics Gastrointestinal Disorders (GID) , by Region USD Billion (2023-2028)
  • Table 110. Digital Therapeutics Respiratory Diseases , by Region USD Billion (2023-2028)
  • Table 111. Digital Therapeutics Smoking Cessation , by Region USD Billion (2023-2028)
  • Table 112. Digital Therapeutics Others , by Region USD Billion (2023-2028)
  • Table 113. Digital Therapeutics: by Sales Channel(USD Billion)
  • Table 114. Digital Therapeutics Business-to-business (B2B) , by Region USD Billion (2023-2028)
  • Table 115. Digital Therapeutics Business-to-consumers (B2C) , by Region USD Billion (2023-2028)
  • Table 116. Digital Therapeutics: by Component(USD Billion)
  • Table 117. Digital Therapeutics Software , by Region USD Billion (2023-2028)
  • Table 118. Digital Therapeutics Devices , by Region USD Billion (2023-2028)
  • Table 119. South America Digital Therapeutics, by Country USD Billion (2023-2028)
  • Table 120. South America Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 121. South America Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 122. South America Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 123. Brazil Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 124. Brazil Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 125. Brazil Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 126. Argentina Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 127. Argentina Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 128. Argentina Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 129. Rest of South America Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 130. Rest of South America Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 131. Rest of South America Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 132. Asia Pacific Digital Therapeutics, by Country USD Billion (2023-2028)
  • Table 133. Asia Pacific Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 134. Asia Pacific Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 135. Asia Pacific Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 136. China Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 137. China Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 138. China Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 139. Japan Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 140. Japan Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 141. Japan Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 142. India Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 143. India Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 144. India Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 145. South Korea Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 146. South Korea Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 147. South Korea Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 148. Taiwan Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 149. Taiwan Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 150. Taiwan Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 151. Australia Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 152. Australia Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 153. Australia Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 154. Rest of Asia-Pacific Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 155. Rest of Asia-Pacific Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 156. Rest of Asia-Pacific Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 157. Europe Digital Therapeutics, by Country USD Billion (2023-2028)
  • Table 158. Europe Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 159. Europe Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 160. Europe Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 161. Germany Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 162. Germany Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 163. Germany Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 164. France Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 165. France Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 166. France Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 167. Italy Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 168. Italy Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 169. Italy Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 170. United Kingdom Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 171. United Kingdom Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 172. United Kingdom Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 173. Netherlands Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 174. Netherlands Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 175. Netherlands Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 176. Rest of Europe Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 177. Rest of Europe Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 178. Rest of Europe Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 179. MEA Digital Therapeutics, by Country USD Billion (2023-2028)
  • Table 180. MEA Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 181. MEA Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 182. MEA Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 183. Middle East Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 184. Middle East Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 185. Middle East Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 186. Africa Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 187. Africa Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 188. Africa Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 189. North America Digital Therapeutics, by Country USD Billion (2023-2028)
  • Table 190. North America Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 191. North America Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 192. North America Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 193. United States Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 194. United States Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 195. United States Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 196. Canada Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 197. Canada Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 198. Canada Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 199. Mexico Digital Therapeutics, by Disease USD Billion (2023-2028)
  • Table 200. Mexico Digital Therapeutics, by Sales Channel USD Billion (2023-2028)
  • Table 201. Mexico Digital Therapeutics, by Component USD Billion (2023-2028)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Digital Therapeutics: by Disease USD Billion (2017-2022)
  • Figure 5. Global Digital Therapeutics: by Sales Channel USD Billion (2017-2022)
  • Figure 6. Global Digital Therapeutics: by Component USD Billion (2017-2022)
  • Figure 7. South America Digital Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific Digital Therapeutics Share (%), by Country
  • Figure 9. Europe Digital Therapeutics Share (%), by Country
  • Figure 10. MEA Digital Therapeutics Share (%), by Country
  • Figure 11. North America Digital Therapeutics Share (%), by Country
  • Figure 12. Global Digital Therapeutics share by Players 2022 (%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. Proteus Digital Health. Inc (United States) Revenue, Net Income and Gross profit
  • Figure 15. Proteus Digital Health. Inc (United States) Revenue: by Geography 2022
  • Figure 16. Omada Health, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 17. Omada Health, Inc (United States) Revenue: by Geography 2022
  • Figure 18. Welldoc, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 19. Welldoc, Inc (United States) Revenue: by Geography 2022
  • Figure 20. Livongo Health (United States) Revenue, Net Income and Gross profit
  • Figure 21. Livongo Health (United States) Revenue: by Geography 2022
  • Figure 22. Mango Health Inc (United States) Revenue, Net Income and Gross profit
  • Figure 23. Mango Health Inc (United States) Revenue: by Geography 2022
  • Figure 24. Global Digital Therapeutics: by Disease USD Billion (2023-2028)
  • Figure 25. Global Digital Therapeutics: by Sales Channel USD Billion (2023-2028)
  • Figure 26. Global Digital Therapeutics: by Component USD Billion (2023-2028)
  • Figure 27. South America Digital Therapeutics Share (%), by Country
  • Figure 28. Asia Pacific Digital Therapeutics Share (%), by Country
  • Figure 29. Europe Digital Therapeutics Share (%), by Country
  • Figure 30. MEA Digital Therapeutics Share (%), by Country
  • Figure 31. North America Digital Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Proteus Digital Health. Inc (United States)
  • Omada Health, Inc (United States)
  • Welldoc, Inc (United States)
  • Livongo Health (United States)
  • Mango Health Inc (United States)
Additional players considered in the study are as follows:
2 Morrow (United States) , Propeller Health (United States) , Twine Health (Fitbit) (United States) , Canary Health (United States)
Select User Access Type

Key Highlights of Report


Dec 2023 249 Pages 67 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Digital Therapeutics Quantitative research analysis
Global Digital Therapeutics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Digital Therapeutics market are Proteus Digital Health. Inc (United States), Omada Health, Inc (United States), Welldoc, Inc (United States), Livongo Health (United States) and Mango Health Inc (United States), to name a few.
"Adoption of IoT and AI in Healthcare Industries " is seen as one of major influencing trends for Digital Therapeutics Market during projected period 2022-2028.

Know More About Global Digital Therapeutics Report?

Have a Query? Click Here

Other Related Reports

Kidney Fibrosis Treatment Comprehensive Study by Therapeutics (Angiotensin Converting Enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasopeptidase In...
$ 3350
Legionella Testing Comprehensive Study by Type (Microbial Culture, DFA Stain, PCR, Others), Application (Water Testing, IVD Testing), End User (Hospital and Clinic, Diagnostic Laboratory) Players and...
$ 3500
Chemotherapy Induced Peripheral Neuropathy Treatment Comprehensive Study by Type (APX-3330, BR-297, Cannabidiol, Dimiracetam, Others), Application (Platinum Agents, Taxanes, Vinca Alkaloids, Others) ...
$ 3500
Animal Therapeutics and Diagnostics Comprehensive Study by Type (Animal Diagnostics Products (Instruments, Consumables), Animal Therapeutics Products (Anti-Parasitic Drugs and Antibiotics, Anti-Infla...
$ 3750
Irritable Bowel Syndrome Treatment Comprehensive Study by Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Ramosetron Hydrochloride, Others), Distribution Channel (Hospital Pharmacies, Online...
$ 3450
Cancer Test Comprehensive Study by Type (Laboratory Tests, Genetic Tests, Imaging, Endoscopy), Application (Bladder Cancer Test, Breast Cancer Test, Cervical Cancer Test, Colorectal (Colon) Cancer Te...
$ 3650